Browse e-DRUG3D database

Cheminformatic Tools and Databases for Pharmacology
Home	e-Drug3D	LEA3D	SENSAAS	IPMC

session 98173 - Total of 4 hits - Display hits per page:

Add another drug(s) by one keyword:
Exemple: “nib“ and click on the Search button (do not press Enter on the keyboard)


1	INN	Class	Route (list)	PK parameters= Cmax; Tmax; F: bioavailability; t1/2: half-life; VD: volume of distribution; Cl: clearance; PPB: plasma protein binding;(EQN means that the equation t1/2 = VD / Cl * 0.693 was used	Primary Target and PDB code of Protein-Drug complex	Targets from DrugCentral	Links
MIDOSTAURIN (has an active metabolite)	MIDOSTAURIN	ATC L01EX10 ANTINEOPLASTIC TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) OR AGGRESSIVE SYSTEMIC MASTOCYTOSIS (ASM) MULTIKINASE TYROSINE KINASE INHIBITOR (FLT3, FLT3 MUTANT KINASES (ITD AND TKD), KIT (WILD TYPE AND D816V MUTANT), PDGFR ALPHA/BETA, VEGFR2, AS WELL AS MEMBERS OF THE SERINE/THREONINE KINASE PKC (PROTEIN KINASE C) FAMILY)	ORAL	Tmax 2 HOUR VD 95.2 LITER PPB 99.8 PERCENT HT 21 HOUR	FLT3 KINASE FLT3 MUTANT KINASES KIT PDGFR VEGFR2 SERINE/THREONINE KINASE PKC PDB 4NCT (HUMAN DYRK1A IN COMPLEX WITH PKC412) LIGAND CODE = 2K2 (link to the list of PDB complexes) Download experimental 3D coordinates of 2K2 with added hydrogens	Receptor-type tyrosine-protein kinase FLT3 UNIPROT P36888 FLT3 more at DrugCentral	EMA ANSM (in French) Inxight Drugs Dailymed Drugs.com SIDER side effects Chemical Probes Portal ChEMBL BindingDB DrugBank
2	INN	Class	Route (list)	PK parameters= Cmax; Tmax; F: bioavailability; t1/2: half-life; VD: volume of distribution; Cl: clearance; PPB: plasma protein binding;(EQN means that the equation t1/2 = VD / Cl * 0.693 was used	Primary Target and PDB code of Protein-Drug complex	Targets from DrugCentral	Links
M MIDOSTAURIN (is an active metabolite)	MIDOSTAURIN	ATC L01EX10 ANTINEOPLASTIC TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) OR AGGRESSIVE SYSTEMIC MASTOCYTOSIS (ASM) MULTIKINASE TYROSINE KINASE INHIBITOR (FLT3, FLT3 MUTANT KINASES (ITD AND TKD), KIT (WILD TYPE AND D816V MUTANT), PDGFR ALPHA/BETA, VEGFR2, AS WELL AS MEMBERS OF THE SERINE/THREONINE KINASE PKC (PROTEIN KINASE C) FAMILY)	-	PPB 99.8 PERCENT HT 32 HOUR	FLT3 KINASE FLT3 MUTANT KINASES KIT PDGFR VEGFR2 SERINE/THREONINE KINASE PKC	Receptor-type tyrosine-protein kinase FLT3 UNIPROT P36888 FLT3 more at DrugCentral	EMA ANSM (in French) Inxight Drugs Dailymed Drugs.com SIDER side effects Chemical Probes Portal ChEMBL BindingDB DrugBank
3	INN	Class	Route (list)	PK parameters= Cmax; Tmax; F: bioavailability; t1/2: half-life; VD: volume of distribution; Cl: clearance; PPB: plasma protein binding;(EQN means that the equation t1/2 = VD / Cl * 0.693 was used	Primary Target and PDB code of Protein-Drug complex	Targets from DrugCentral	Links
M MIDOSTAURIN (is an active metabolite)	MIDOSTAURIN	ATC L01EX10 ANTINEOPLASTIC TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) OR AGGRESSIVE SYSTEMIC MASTOCYTOSIS (ASM) MULTIKINASE TYROSINE KINASE INHIBITOR (FLT3, FLT3 MUTANT KINASES (ITD AND TKD), KIT (WILD TYPE AND D816V MUTANT), PDGFR ALPHA/BETA, VEGFR2, AS WELL AS MEMBERS OF THE SERINE/THREONINE KINASE PKC (PROTEIN KINASE C) FAMILY)	-	PPB 99.8 PERCENT HT 482 HOUR	FLT3 KINASE FLT3 MUTANT KINASES KIT PDGFR VEGFR2 SERINE/THREONINE KINASE PKC	Receptor-type tyrosine-protein kinase FLT3 UNIPROT P36888 FLT3 more at DrugCentral	EMA ANSM (in French) Inxight Drugs Dailymed Drugs.com SIDER side effects Chemical Probes Portal ChEMBL BindingDB DrugBank
4	INN	Class	Route (list)	PK parameters= Cmax; Tmax; F: bioavailability; t1/2: half-life; VD: volume of distribution; Cl: clearance; PPB: plasma protein binding;(EQN means that the equation t1/2 = VD / Cl * 0.693 was used	Primary Target and PDB code of Protein-Drug complex	Targets from DrugCentral	Links
M MIDOSTAURIN (is an active metabolite)	MIDOSTAURIN	ATC L01EX10 ANTINEOPLASTIC TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) OR AGGRESSIVE SYSTEMIC MASTOCYTOSIS (ASM) MULTIKINASE TYROSINE KINASE INHIBITOR (FLT3, FLT3 MUTANT KINASES (ITD AND TKD), KIT (WILD TYPE AND D816V MUTANT), PDGFR ALPHA/BETA, VEGFR2, AS WELL AS MEMBERS OF THE SERINE/THREONINE KINASE PKC (PROTEIN KINASE C) FAMILY)	-	PPB 99.8 PERCENT HT 482 HOUR	FLT3 KINASE FLT3 MUTANT KINASES KIT PDGFR VEGFR2 SERINE/THREONINE KINASE PKC	Receptor-type tyrosine-protein kinase FLT3 UNIPROT P36888 FLT3 more at DrugCentral	EMA ANSM (in French) Inxight Drugs Dailymed Drugs.com SIDER side effects Chemical Probes Portal ChEMBL BindingDB DrugBank